The strengths of this study were the successful establishment of the CI-AKI (not only assessed by serum creatinine and blood urea nitrogen but also by urine analysis-based studies), potential translational evidence showing that rosiglitazone could have therapeutic effects in such disease, and identifying the underlying mechanism of rosiglitazone in alleviating AKI by regulating the PPARγ/NLRP3 signaling pathway. This evidence concerns the gene PPARG and acute kidney injury.